Case Report

The Successful Treatment of a Case of Linear Psoriasis with Ixekizumab

Sara Ghoneim,1 Alvaro J. Ramos-Rodriguez,2 Fernando Vazquez de Lara,2 and Lauren Bonomo3

1Saba University School of Medicine, The Bottom, Netherlands
2Icahn School of Medicine at Mount Sinai West, New York, NY, USA
3Icahn School of Medicine at Mount Sinai, New York, NY, USA

Correspondence should be addressed to Sara Ghoneim; s.ghoneim@saba.edu

Received 10 August 2017; Accepted 10 October 2017; Published 2 November 2017

1. Introduction

Linear psoriasis is a rare clinical variation of psoriasis that manifests segmentally along the lines of Blaschko. The pathogenesis remains unclear, though some have proposed it could be explained by the well-established concept of genetic mosaicism [1]. Happle (1991) suggested that the loss of heterozygosity in somatic cells during early embryogenesis results in somatic recombination with daughter cells. Subsequently, these daughter cells go on to become clonal stem cells proliferating in a linear pattern during the embryonic development of the skin. A major differential diagnosis for linear psoriasis is inflammatory linear verrucous epidermal nevus (ILVEN). The treatment of linear psoriasis is often challenging, with inadequate response to biological agents reported in the literature. We report a case of a 25-year-old African-American female who presented with asymptomatic hyperkeratotic papules along the lines of Blaschko and was subsequently diagnosed with linear psoriasis. After failing conventional treatment regimens, the patient received a trial of ixekizumab with complete resolution of cutaneous lesions reported after 4 months and only 8 doses of the anti-IL-17 biologic agent.

2. Case Report

A 25-year-old African-American female presented to our clinic with asymptomatic lesions linearly arranged over her left upper extremity. The initial lesion first appeared fifteen years ago and new lesions gradually appeared over time. She denied joint pain and/or a history of infections prior to lesion development. Her past medical history was significant only for posttraumatic distress disorder and depression. There was no personal or family history of psoriasis or other dermatologic disease. Prior to presentation in our clinic, she had a skin biopsy of the right forearm which showed chronic spongiotic dermatitis with parakeratotic foci and superficial perivascular mononuclear infiltrates. No deep dermal or periadnexal infiltrates were seen and periodic acid-Schiff staining was negative for fungal organisms. Based on the results, both lichen striatus and linear psoriasis were considered as potential diagnosis, and she was started on high-potency topical steroids. A month later, the patient was referred to our clinic when she failed to respond to treatment.

Physical examination revealed hyperkeratotic and scaly gray papules coalescing into a linear plaque of the right
dorsal fifth finger extending medially to the right elbow (Figure 1(a)). Of note, scaly papules were also present on a tattoo above the right elbow (Figure 1(b)). There was no nail or palmoplantar involvement. The differential diagnosis included linear psoriasis and ILVEN. The isomorphic reaction seen within the patient’s tattoo (Koebner phenomenon) favored a diagnosis of psoriasis. A skin biopsy and electrodessication of one papule on her right dorsal fifth finger were performed. Histological examination of the specimen revealed parakeratosis with uniformly acanthotic epidermis (Figure 2). At a follow-up visit 2 weeks later, the patient developed new papules with similar morphology in the area that was previously electrodessicated (Figure 3(a)). This new episode of Koebnerization and histological findings further supported our diagnosis of linear psoriasis and the decision was made to initiate treatment with ixekizumab, a monoclonal antibody targeting interleukin-17A. Four months later and after 8 doses of ixekizumab, we observed almost-complete resolution of the cutaneous lesions (Figures 3(b) and 3(c)).

3. Case Discussion

Linear psoriasis is a rare clinical presentation of psoriasis characterized by the linear distribution of psoriatic lesions along the lines of Blaschko. The main differential diagnosis is ILVEN. Gross morphological distinction between these two entities is difficult. Furthermore, the two entities share similar histological findings and the coexistence of ILVEN and psoriasis has also been reported [3, 4]. Histological examination of ILVEN shows areas of hypergranulosis and orthokeratosis alternating with areas of hypogranulosis and...
parakeratosis [5]. Under these circumstances, immunohistochemical studies are helpful in distinguishing these two cutaneous disorders. For example, involucrin is a marker whose expression is absent in the parakeratotic areas of ILVEN but present in psoriasis [6]. Moreover, the number of Ki-67 positive nuclei is higher in psoriasis compared to ILVEN, while the number of keratin-10 positive cells is higher in ILVEN [7]. In practice, these tests are rarely ordered. It is often more practical to simply initiate therapy for psoriasis if the diagnosis is suspected.

We are now able to conclude that linear psoriasis was the correct diagnosis in this case based on several observations. First, our patient's lesions were nonpruritic, and ILVEN tends to be more pruritic than psoriatic lesions [8]. Additionally, Koebner phenomenon affects 25–30% of patients with psoriasis [9], and our patient developed lesions on her tattoo and on the electrodessicated site of her right dorsal hand. To our knowledge, Koebner phenomenon has not been described in any reported case of ILVEN. Finally, ILVEN responds minimally to antipsoriatic agents, and our patient had a remarkable response to only 8 doses of the biologic agent ixekizumab, a drug approved by the US Food and Drug Administration in 2016 for the treatment for moderate to severe plaque psoriasis.

It is known from a small number of reports that segmental manifestations of psoriasis respond less favorably to systemic therapies such as methotrexate, acitretin, and, more recently, biologics [3, 10–13]. The chronicity and resistance of linear psoriasis to available antipsoriatic agents were suggested to be in part due to the loss of heterozygosity in cells where the lesions occur [12]. In our literature review, patients treated with either anti-IL-23 or tumor necrosis-alpha inhibitor agents had significant improvements on all of the types of psoriasis except in linear psoriasis (Table 1). Multiple studies have also demonstrated that even though psoriatic lesions might look similar, they differ substantially in the activation status of inflammatory and cytokine pathways and such networks might contribute to the different treatment responses observed with biologic agents [14]. Furthermore, by analyzing psoriasis transcriptome in nontreated biopsied lesions, one study was able to differentiate between etanercept responders and nonresponders [15]. This heterogeneity in response further underscores the potential role of gene-expression profiling as potential predictors of response to biologics.
Table 1: Summary of reported cases of linear psoriasis treated with a biological agent.

| Authors (year) | Gender | Age | Distribution of linear psoriasis (LP) | Other features | Biological agent used and outcome |
|---------------|--------|-----|---------------------------------------|----------------|----------------------------------|
| Colombo et al. (2011) [3] | Male | 67 years | Middle of ventral trunk and left side of arm, hand, thigh, knee, and tibia | Psoriatic arthritis and diffuse plaque psoriasis. Failed to respond to acitretin, cyclosporine, and methotrexate | Plaque psoriasis responded to etanercept but not LP |
| Rott et al. (2007) [10] | Male | 11 years | Left side of the body | Psoriatic arthritis, nail changes. Failed methotrexate, cyclosporine and etanercept | Psoriatic arthritis responded to infliximab but not LP |
| Sfia et al. (2009) [11] | Male | 29 years | Left arm and left leg | Additional psoriatic plaques on the body | Psoriatic plaques responded to infliximab but not LP |
| Arnold et al. (2010) [12] | Male | 50 years | Left flank | Diffuse plaque psoriasis. Failed to respond to topical steroids, PUVA, UVB, cyclosporine, and etanercept | Plaque psoriasis responded to adalimumab but not LP |
| Weng and Tsai (2017) [13] | Male | 27 years | Right upper arm, shoulder, and back | In addition to plaque psoriasis. Failed to respond to methotrexate, acitretin, topical vitamin D3 analogs and steroids | Plaque psoriasis responded to ustekinumab but not LP |
| Ghoneim et al. (2017) | Female | 25 years | Dorsum of right hand, forearm and arm, and suprapubic region, left thigh and occiput | Failed topical high-potency steroids | Linear psoriasis responded favorably to 8 doses of ixekizumab |

There are no current formal guidelines for the treatment of linear psoriasis, and larger studies are needed to determine optimal therapy for this rare variant. In our case, the patient responded favorably to ixekizumab, which opens the possibility of using new biologic agents and individualized therapy in patients with recalcitrant linear psoriasis.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

[1] R. Happle, “Somatic recombination may explain linear psoriasis,” Journal of Medical Genetics, vol. 28, no. 5, p. 337, 1991.
[2] Y. Oram and et al., “Bilateral inflammatory linear verrucous epidermal nevus associated with psoriasis,” Cutis, vol. 57, 275, no. 4, p. 278, 1996.
[3] L. Colombo and et al., “Superimposed linear psoriasis: low effectiveness of biologic therapy,” Giornale Italiano di Dermatologia e Venereologia, vol. 146, no. 4, p. 311–313, 2011.
[4] T. Hofer, “Does inflammatory linear verrucous epidermal nevus represent a segmental type 1/type 2 mosaic of psoriasis?” Dermatology, vol. 212, no. 2, pp. 103–107, 2006.
[5] A. Brinca, F. Santiago, D. Serra, P. Andrade, R. Vieira, and A. Figueiredo, “Linear Psoriasis – A Case Report,” Case Reports in Dermatology, vol. 3, no. 1, pp. 8–12, 2011.
[6] F. R. Ferreira, N. G. Di Chiaccio, M. L. De Alvarenga, and S. H. Mandelbaum, “Involucrin in the differential diagnosis between linear psoriasis and inflammatory linear verrucous epidermal nevus: A report of one case,” Anais Brasileiros de Dermatologia, vol. 88, no. 4, pp. 604–607, 2013.
[7] W. H. Vissers and et al., “Immunohistochemical differentiation between inflammatory linear verrucous epidermal nevus (ILVEN) and psoriasis,” European Journal of Dermatology, vol. 14, no. 4, pp. 216–220, 2004.
[8] J. Altman and A. H. Mehregan, “Inflammatory Linear Verrucose Epidermal Nevus,” JAMA Dermatology, vol. 104, no. 4, pp. 385–389, 1971.
[9] N. Kluger, E. Estève, S. Fouéré, F. Dupuis-Fourdan, M. Jegou, and C. Lévy-Rameau, “Tattooing and psoriasis: a case series and review of the literature,” International Journal of Dermatology, vol. 56, no. 8, pp. 822–827, 2017.
[10] S. Rott, R. M. Küster, and U. Mrowietz, “Successful treatment of severe psoriatic arthritis with infliximab in an 11-year-old child suffering from linear psoriasis along lines of Blaschko [5],” British Journal of Dermatology, vol. 157, no. 1, pp. 191-192, 2007.
[11] M. Sfia, B. Roth-Mall, M.-C. Tortel, J.-C. Guillaume, and B. Cribier, “Blaschko-linear psoriasis revealed by infliximab therapy,” Annales de Dermatologie et de Venereologie, vol. 136, no. 12, pp. 898–903, 2009.
[12] A. W. Arnold, R. Happle, and P. H. Itin, “Superimposed linear psoriasis unmasked by therapy with adalimumab,” European Journal of Dermatology, vol. 20, no. 5, pp. 573-574, 2010.
[13] H. Weng and T. Tsai, “Response of superimposed linear psoriasis to ustekinumab: A case report,” Indian Journal of
[14] J. Karczewski, B. Poniedziałek, P. Rzymski, and Z. Adamski, “Factors affecting response to biologic treatment in psoriasis,” *Dermatologic Therapy*, vol. 27, no. 6, pp. 323–330, 2014.

[15] W. R. Swindell, A. Johnston, J. J. Voorhees, J. T. Elder, and J. E. Gudjonsson, “Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients,” *BMC Genomics*, vol. 14, no. 1, article 527, 2013.